Escolar Documentos
Profissional Documentos
Cultura Documentos
348
LEVEL OF EVIDENCE: II
he combined oral contraceptive pill (OCP) currently being used by more than 100 million
women worldwide1 contains both estrogen and progestin in various combinations. The main mechanism
of action of the steroid is inhibition of follicular
development and prevention of ovulation by pituitary
and hypothalamic suppression of follicle-stimulating
hormone and luteinizing hormone.12 Other secondary
mechanisms of contraceptive activity include progestogenic induction of hostile cervical mucus and of an
endometrial environment that is unfavorable for implantation.3 A predominant progestational effect of
combined OCP on the endometrium includes an
arrest of glandular proliferation, induction of pseudosecretion, and stromal edema followed by decidualized stroma with granulocytes and thin sinusoidal
blood vessels. Prolonged use results in progressive
endometrial atrophy.4 This latter property has been
used for the treatment of dysfunctional uterine bleeding and endometrial hyperplasia. Currently, pretreatment with combined OCPs also is used for diagnostic
and operative hysteroscopy in which the visualization
Endometrial preparation
Other protocol
n=93
Standard estrogen protocol
n=295
Other pathology or
incomplete data
n=10
Talukdar et al
349
RESULTS
Of the 488 patients with frozen embryo transfer
between 2008 and 2010, 137 patients were within the
same age group (30 45 years), had the same protocol
for endometrial preparation before embryo transfer,
and had a history of combined OCP use more than 2
years before treatment (Fig. 1).
As illustrated in Table 1, 30 out of the 137
patients (21.9%) had an endometrial thickness less
than 7 mm on day 10 of the frozen embryo transfer
Age (y)
BMI (kg/m2)
Age at menarche (y)
Infertility
Primary
Secondary
Duration of infertility (m)
Endometrial thickness (mm)
Combined OCP use (y)
Day of starting progesterone
Cycle cancellation
Pregnancy
Endometrial Thickness
Less Than 7 mm (n30)
Endometrial Thickness
7 mm or More (n107)
P*
36.273.40
22.52.57
12.31.18
36.063.32
22.72.21
11.81.4
.632
.308
.012
66 (62)
41 (38)
22.412.08
10.031.45
5.84.52
10.10.29
4 (4/107)
27 (29/107)
.410
16 (53)
14 (47)
23.011.64
6.060.62
9.84.54
14.41.62
23 (7/30)
13 (4/30)
.725
.001
.001
.001
.002
.150
350
Talukdar et al
Endometrium
Less Than 7 mm
Endometrium
7 mm or More
Total
11 (36.65)
77 (71.96)
88
19 (63.35)
30 (28.04)
49
30
107
137
16
16
14
14
Endometrial thickness (mm)
12
10
8
6
4
12
10
8
6
4
Endometrium
Less Than 7 mm
Endometrium
7 mm or More
Total
4 (13.34)
47 (43.9)
51
26 (86.66)
60 (56.1)
86
30
107
137
Talukdar et al
351
DISCUSSION
In the present study, the endometrial thickness was
recorded in women of similar ages who received the
same endometrial preparation for frozen embryo
transfer. All had a history of combined OCP use of
varying duration, and all had stopped the combined
OCP 2 years before frozen embryo transfer.
The only literature we could find addressing
long-term combined OCP use (defined as 5 years or
more) and fertility suggests that there is no adverse
effect on endometrial growth or pregnancy outcome.7
In fact, the authors observed a reduced time to
pregnancy in women using combined OCPs for 5 or
more years compared with less than 5 years or no use
at all. The authors speculated that the combined OCP
may prevent the possibility of endometriosis progression by minimizing endometrial proliferation and
menstrual bleeding, thereby improving the chance to
352
Talukdar et al
mm.19 In a previous study of infertile women receiving estrogen replacement, an endometrial thickness of
7 mm or more was more likely to have an in phase
endometrium compared with an endometrial thickness of less than 7 mm.20 In our study, we found that
the average endometrial thickness in the thin endometrium group was 6.060.62 mm, whereas it was
10.031.45 mm in the 7 mm or greater endometrial
thickness group. With longer duration of treatment
with estrogen, the thin endometrium group may catch
up and frozen embryo transfer is possible, although
further along in the cycle. A total of seven cycles had
to be cancelled in the less than7 mm group because of
persistently thin endometrium.
Currently, much focus is on endometrial stem
cells and their important role as the regenerator of
the human endometrium. Although endometrial growth
and differentiation are primarily regulated by estrogen
and progesterone, it is postulated that the clonogenic
activity of the endometrial epithelial and stromal cells is
actually responsible for the remarkable regenerative
capacity of the human endometrium. Several growth
factors have been identified to support clonogenicity.21
Kjiana et al21 demonstrated for the first time to our
knowledge that inactive endometrium, ie, endometrium
of women using oral contraceptive therapy and postmenopausal women, also contains clonogenic epithelial
and stromal cells. The endometrium regenerates on
cessation of oral contraceptive therapy and, in postmenopausal women, when hormone replacement therapy is started. However, they also demonstrated that the
cloning efficiencies were lower in inactive endometrium
than either the proliferative or the secretory phase
endometrium. This suggests that the number of clonogenic cells increases with cycling21 and supports the
possibility that with a prolonged period of inactivity
there is significant suppression of the stem cells, so that
the endometrium fails to recover even with estrogen
stimulation or needs a much prolonged or higher-dose
stimulation for optimal functioning.
We acknowledge that the present study is limited
by several factors. The sample size is small and we
also lack information on the exact composition of
the combined OCP (dose and type of estrogen and
progestin) used. At present, we do not have knowledge of the mechanism of this potential adverse effect
of combined OCPs and a biologic explanation for this
phenomenon awaits further research. However, we
believe our findings of an association between longterm use (5 years or more) of combined OCPs and
persisting thin endometrium in women undergoing
frozen embryo transfer cycles demonstrates an unusual and, until now, unidentified side effect of com-
Talukdar et al
353
354
Talukdar et al